{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:02:28Z","timestamp":1761919348518},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T00:00:00Z","timestamp":1275955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00280-010-1349-2","type":"journal-article","created":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T11:40:35Z","timestamp":1275910835000},"page":"769-774","source":"Crossref","is-referenced-by-count":16,"title":["Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract"],"prefix":"10.1007","volume":"67","author":[{"given":"Kang Su","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Young","family":"Joung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Kyung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Chang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Soo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsoo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"1349_CR1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0090-4295(98)00295-7","volume":"52","author":"MC Hall","year":"1998","unstructured":"Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52:594\u2013601","journal-title":"Urology"},{"key":"1349_CR2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/modpathol.3800529","volume":"19","author":"C Langner","year":"2006","unstructured":"Langner C, Hutterer G, Chromecki T, Winkelmayer I, Rehak P, Zigeuner R (2006) pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract. Mod Pathol 19:272\u2013279","journal-title":"Mod Pathol"},{"key":"1349_CR3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al (2009) Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115:1224\u20131233","journal-title":"Cancer"},{"key":"1349_CR4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.juro.2009.05.011","volume":"182","author":"NJ Hellenthal","year":"2009","unstructured":"Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182:900\u2013906","journal-title":"J Urol"},{"key":"1349_CR5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1593\/neo.06661","volume":"9","author":"JE Uhm","year":"2007","unstructured":"Uhm JE, Lim HY, Kim WS, Choi HY, Lee HM, Park BB et al (2007) Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia 9:18\u201322","journal-title":"Neoplasia"},{"key":"1349_CR6","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Maase von der","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077","journal-title":"J Clin Oncol"},{"key":"1349_CR7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer Sr","year":"1992","unstructured":"Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066\u20131073","journal-title":"J Clin Oncol"},{"key":"1349_CR8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-6143.2005.01140.x","volume":"6","author":"ED Poggio","year":"2006","unstructured":"Poggio ED, Wang X, Weinstein DM, Issa N, Dennis VW, Braun WE et al (2006) Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 6:100\u2013108","journal-title":"Am J Transplant"},{"key":"1349_CR9","unstructured":"Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0. http:\/\/ctep.info.nih.gov\/reporting\/ctc.html . http:\/\/ctep.info.nih.gov\/reporting\/ctc.html"},{"key":"1349_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1349_CR11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(06)70803-8","volume":"7","author":"WC Huang","year":"2006","unstructured":"Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735\u2013740","journal-title":"Lancet Oncol"},{"key":"1349_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2007.08.156","volume":"179","author":"SM Lucas","year":"2008","unstructured":"Lucas SM, Stern JM, Adibi M, Zeltser IS, Cadeddu JA, Raj GV (2008) Renal function outcomes in patients treated for renal masses smaller than 4\u00a0cm by ablative and extirpative techniques. J Urol 179:75\u201379 (discussion 79\u201380)","journal-title":"J Urol"},{"key":"1349_CR13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506\u2013513","journal-title":"Cancer"},{"key":"1349_CR14","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2005.04.3091","volume":"24","author":"GV Raj","year":"2006","unstructured":"Raj GV, Iasonos A, Herr H, Donat SM (2006) Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 24:3095\u20133100","journal-title":"J Clin Oncol"},{"key":"1349_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","volume":"21","author":"PE Kintzel","year":"1995","unstructured":"Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21:33\u201364","journal-title":"Cancer Treat Rev"},{"key":"1349_CR16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","volume":"23","author":"I Arany","year":"2003","unstructured":"Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460\u2013464","journal-title":"Semin Nephrol"},{"key":"1349_CR17","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1200\/JCO.2006.08.0564","volume":"24","author":"JA Garcia","year":"2006","unstructured":"Garcia JA, Dreicer R (2006) Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 24:5545\u20135551","journal-title":"J Clin Oncol"},{"key":"1349_CR18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1","volume":"77","author":"R Petrioli","year":"1996","unstructured":"Petrioli R, Frediani B, Manganelli A, Barbanti G, De Capua B, De Lauretis A et al (1996) Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77:344\u2013351","journal-title":"Cancer"},{"key":"1349_CR19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","volume":"80","author":"J Bellmunt","year":"1997","unstructured":"Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966\u20131972","journal-title":"Cancer"},{"key":"1349_CR20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","volume":"52","author":"L Dogliotti","year":"2007","unstructured":"Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52:134\u2013141","journal-title":"Eur Urol"},{"key":"1349_CR21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2007.01.017","volume":"52","author":"S Culine","year":"2007","unstructured":"Culine S (2007) Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin? Eur Urol 52:9\u201310","journal-title":"Eur Urol"},{"key":"1349_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.clinbiochem.2006.10.014","volume":"40","author":"S Herget-Rosenthal","year":"2007","unstructured":"Herget-Rosenthal S, Bokenkamp A, Hofmann W (2007) How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 40:153\u2013161","journal-title":"Clin Biochem"},{"key":"1349_CR23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.V71118","volume":"7","author":"M Sambataro","year":"1996","unstructured":"Sambataro M, Thomaseth K, Pacini G, Robaudo C, Carraro A, Bruseghin M et al (1996) Plasma clearance rate of 51Cr-EDTA provides a precise and convenient technique for measurement of glomerular filtration rate in diabetic humans. J Am Soc Nephrol 7:118\u2013127","journal-title":"J Am Soc Nephrol"},{"key":"1349_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"S Quasthoff","year":"2002","unstructured":"Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9\u201317","journal-title":"J Neurol"},{"key":"1349_CR25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOO.0b013e3282eee452","volume":"15","author":"LP Rybak","year":"2007","unstructured":"Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364\u2013369","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"1349_CR26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.bjc.6604113","volume":"98","author":"KS Han","year":"2008","unstructured":"Han KS, Joung JY, Kim TS, Jeong IG, Seo HK, Chung J et al (2008) Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 98:86\u201390","journal-title":"Br J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1349-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1349-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1349-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T01:22:32Z","timestamp":1635470552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1349-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1349-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,8]]}}}